Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MNPR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMonopar reports Phase 3 trial shows ALXN1840 beats standard care for neurologic Wilson disease
Filed April 20, 2026 · Period ending April 19, 2026 · ~1 min read
Key Changes
-
high
Phase 3 FoCus trial analyses showed ALXN1840 (tiomolibdate choline) delivered greater neurologic benefit than standard of care in Wilson disease patients with neurologic symptoms at baseline.
Item 8.01 view on EDGAR → -
high
Results were presented at the American Academy of Neurology Annual Meeting (April 18-22, 2026), marking a key clinical milestone that could support regulatory approval.
Press Release verify on EDGAR →
Summary
Monopar Therapeutics announced positive Phase 3 trial results for ALXN1840, its experimental treatment for Wilson disease. New analyses from the FoCus trial demonstrated that patients with neurologic symptoms at baseline experienced greater neurologic benefit on ALXN1840 compared to standard of care treatment. The company presented these findings at a major neurology conference in April 2026.
For retail investors, this represents a significant clinical validation of Monopar's lead drug candidate in a rare disease with limited treatment options. Positive Phase 3 data typically supports regulatory filings and potential commercialization. Investors should watch for the company's next steps: whether Monopar announces plans to file for FDA approval, seeks a partnership, or provides additional trial details that could affect the drug's commercial prospects and timeline to market.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 19, 2026, Monopar Therapeutics Inc. (“Monopar”) issued a press release announcing the presentation of new analyses from the Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline) showing greater neurologic benefit versus standard of care in Wilson disease patients with neurologic symptoms at baseline.
Monopar disclosed new analyses from its Phase 3 FoCus trial demonstrating that ALXN1840 (tiomolibdate choline) provided greater neurologic benefit compared to standard of care in Wilson disease patients who had neurologic symptoms at the start of treatment. The company presented these findings at the American Academy of Neurology Annual Meeting held April 18-22, 2026.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Poster Presentation on Greater Clinical Benefit of ALXN1840 Versus Standard of Care in Neurologic Wilson Disease Patients in Phase 3 FoCus Trial.
The company disclosed results from its Phase 3 FoCus trial demonstrating that ALXN1840 provided greater clinical benefit compared to standard of care treatment in patients with neurologic Wilson disease. This represents a key clinical milestone for the drug candidate, potentially supporting regulatory approval and commercialization.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify